The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans
Abstract
Objectives—: Incretin-based therapies for the treatment of type 2 diabetes mellitus improve plasma lipid profiles and postprandial lipemia, but their exact mechanism of action remains unclear. Here, we examined the acute effect of the glucagon-like peptide-1 receptor agonist, exenatide, on intestinal and hepatic triglyceride-rich lipoprotein production and clearance in healthy humans. Methods and Results—: Fifteen normolipidemic, normoglycemic men underwent 2 studies each (SC 10 μg exenatide versus placebo), 4 to 6 weeks apart, in random order, in which triglyceride-rich lipoprotein particle kinetics were examined with a primed, constant infusion of deuterated leucine and analyzed by multicompartmental modeling under pancreatic clamp conditions. A fed state was maintained during each study by infusing a high-fat, mixed macronutrient, liquid formula at a constant rate directly into the duodenum via a nasoduodenal tube. Exenatide significantly suppressed the plasma concentration and production rate of triglyceride-rich lipoprotein-apolipoprotein B-48, but not of triglyceride-rich lipoprotein-apolipoprotein B-100. Conclusions—: These results suggest a possible direct effect of exenatide on intestinal lipoprotein particle production, independent of changes in weight gain and satiety as seen in long-term studies and independent of changes in gastric emptying. This finding expands our understanding of the effects of exenatide in metabolic regulation beyond its primary therapeutic role in regulation of glucose homeostasis. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov , NCT01056549.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In one study, osmotic diarrhea occurred 8 h after infusion of GLP-1 peptide (47), and GLP-1RAs have been shown to reduce intestinal uptake of glucose and lipids (48, 49).”
From Safety of Semaglutide (2021) · cites this paper as [49]
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Insulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,372
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 645
Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/endo.137.7.8770921 · Cited by 622
Pratley, R. E., Nauck, M. A., Bailey, T. S., Montanya, E., Cuddihy, R. M., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 587
Lewis, G., Uffelman, K., Szeto, L., Weller, B., & Steiner, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117633 · Cited by 533
Self-citationGupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477
Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R. (2006) · Diabetologia · doi:10.1007/s00125-006-0340-2 · Cited by 336
Cited by
Sorted by citations
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440
Vinarov, Z., Abdallah, M., Agúndez, J. A. G., Allegaert, K., Basit, A. W., Braeckmans, M., Ceulemans, J., Corsetti, M., Griffin, B. T., Grimm, M. F., et al. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105812 · Cited by 396
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“These findings are further supported by a study revealing that GLP-1 analogs impact the production of triglyceride-rich lipoproteins in normoglycaemic men (234).”
ResultSmits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
Sun, F., Wu, S., Wang, J., Guo, S., Chai, S., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.11.008 · Cited by 232
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212
Self-citationSarafidis, P. A., Ferro, C. J., Morales, E., Ortíz, A., Małyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J. M., Fouque, D. P., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy407 · Cited by 216
New insights into the regulation of chylomicron production
Dash, S., Xiao, C., Morgantini, C., & Lewis, G. F. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034338 · Cited by 194
Self-citationPostprandial hypertriglyceridemia as a coronary risk factor
Borén, J., Matikainen, N., Adiels, M., & Taskinen, M.-R. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.015 · Cited by 182
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Yabut, J. M., & Drucker, D. J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac018 · Cited by 189
Koska, J., Sands, M., Burciu, C., D’Souza, K. M., Raravikar, K., Liu, J., Truran, S., Franco, D. A., Schwartz, E. A., Schwenke, D. C., et al. (2015) · Diabetes · doi:10.2337/db14-0976 · Cited by 174
Recent advances in pharmacotherapy for hypertriglyceridemia
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.07.002 · Cited by 166
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157
GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
Abdalqadir, N., & Adeli, K. (2022) · Microorganisms · doi:10.3390/microorganisms10102061 · Cited by 119
Jácome-Sosa, M., & Parks, E. J. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000080 · Cited by 123
Heuvelman, V. D., Van Raalte, D. H., & Smits, M. M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz323 · Cited by 106
Review article: a comparison of glucagon‐like peptides 1 and 2
Janssen, P., Rotondò, A., Mulè, F., & Tack, J. F. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12092 · Cited by 105
Varin, E. M., Mulvihill, E. E., Baggio, L. L., Koehler, J. A., Cao, X., Seeley, R. J., & Drucker, D. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.055 · Cited by 104
Dash, S., Xiao, C., Morgantini, C., Szeto, L., & Lewis, G. F. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.302342 · Cited by 102
Self-citationRaka, F., Farr, S., Kelly, J., Stoianov, A. M., & Adeli, K. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00036.2019 · Cited by 101
Miyagawa, J., Odawara, M., Takamura, T., Iwamoto, N., Takita, Y., & Imaoka, T. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12534 · Cited by 98
Glucagon-Like Peptide-2 Regulates Release of Chylomicrons From the Intestine
Dash, S., Xiao, C., Morgantini, C., Connelly, P. W., Patterson, B. W., & Lewis, G. F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.037 · Cited by 97
Self-citationGastaldelli, A., Gaggini, M., Daniele, G., Ciociaro, D., Cersosimo, E., Tripathy, D., Triplitt, C., Fox, P., Musi, N., DeFronzo, R., et al. (2016) · Hepatology · doi:10.1002/hep.28827 · Cited by 96
GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
Yu, J. H., Park, S. Y., Lee, D. Y., Kim, N. H., & Seo, J. A. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.22.001 · Cited by 97
Chylomicrons: Advances in biology, pathology, laboratory testing, and therapeutics
Julve, J., Martín-Campos, J. M., Escolá‐Gil, J. C., & Blanco‐Vaca, F. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.02.004 · Cited by 94
Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives
Jin, T., & Weng, J. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00069.2016 · Cited by 87
Postprandial Hypertriglyceridemia and Cardiovascular Disease: Current and Future Therapies
Chan, D. C., Pang, J., Romic, G., & Watts, G. F. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0309-9 · Cited by 79
The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
Drucker, D. J. (2018) · Diabetes · doi:10.2337/dbi18-0008 · Cited by 81
Recent advances in triacylglycerol mobilization by the gut
Xiao, C., Stahel, P., Carreiro, A. L., Buhman, K. K., & Lewis, G. F. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.12.001 · Cited by 77
Self-citationSmits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74
Vergès, B., Duvillard, L., Pais de Barros, J. P., Bouillet, B., Baillot-Rudoni, S., Rouland, A., Sberna, A.-L., Petit, J.-M., Degrace, P., & Demizieux, L. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.310990 · Cited by 75
Xiao, C., Dash, S., Morgantini, C., Patterson, B. W., & Lewis, G. F. (2014) · Diabetes · doi:10.2337/db13-1654 · Cited by 73
Self-citationModification of lipoprotein metabolism and function driving atherogenesis in diabetes
Luciani, L., Pedrelli, M., & Parini, P. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117545 · Cited by 72
How glucagon-like peptide 1 receptor agonists work
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Endocrine Connections · doi:10.1530/ec-21-0130 · Cited by 71
“The figure illustrates GLP-1(7-36) amide.”
Austregésilo de Athayde De Hollanda Morais, B., Martins Prizão, V., de Moura de Souza, M., Ximenes Mendes, B., Rodrigues Defante, M. L., Cosendey Martins, O., & Rodrigues, A. M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108834 · Cited by 68
Liao, C., Liang, X., Zhang, X., & Li, Y. (2023) · PLOS ONE · doi:10.1371/journal.pone.0289616 · Cited by 63
Farr, S., Baker, C., Naples, M., Taher, J., Iqbal, J., Hussain, M. M., & Adeli, K. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304873 · Cited by 62
Xie, C., Jones, K. L., Rayner, C. K., & Wu, T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090790 · Cited by 64
GLP-1 based therapies: clinical implications for gastroenterologists
Smits, M. M., van Raalte, D. H., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., & Cahen, D. L. (2016) · Gut · doi:10.1136/gutjnl-2015-310572 · Cited by 62
Xiao, C., Dash, S., Morgantini, C., Adeli, K., & Lewis, G. F. (2015) · Diabetes · doi:10.2337/db14-1706 · Cited by 61
Self-citationNew and emerging regulators of intestinal lipoprotein secretion
Xiao, C., Dash, S., Morgantini, C., & Lewis, G. F. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.047 · Cited by 60
Self-citationNovel Role of Enteral Monosaccharides in Intestinal Lipoprotein Production in Healthy Humans
Xiao, C., Dash, S., Morgantini, C., & Lewis, G. F. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300769 · Cited by 58
Self-citationJanssen, L. G. M., Nahon, K. J., Bracké, K. F. M., van den Broek, D., Smit, R., Sardjoe Mishre, A. S. D., Koorneef, L. L., Martinez-Tellez, B., Burakiewicz, J., Kan, H. E., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154167 · Cited by 54
Intestinal lipid absorption and transport in type 2 diabetes
Vergès, B. L. (2022) · Diabetologia · doi:10.1007/s00125-022-05765-8 · Cited by 58
Ussher, J. R., Greenwell, A. A., Nguyen, M.-A., & Mulvihill, E. E. (2022) · Diabetes · doi:10.2337/dbi20-0049 · Cited by 51
Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 54
Brunell, S. C., Toth, P. P., Ramírez, G., Cobble, Chilton, & Chiquette (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37969 · Cited by 49
Liu, D., Pang, J., Shao, W., Gu, J., Zeng, Y., He, H. H., Ling, W., Qian, X., & Jin, T. (2021) · Hepatology · doi:10.1002/hep.31856 · Cited by 48
Postprandial Dyslipidemia: Pathophysiology and Cardiovascular Disease Risk Assessment.
Higgins, V., & Adeli, K. (2017) · PubMed Central · Cited by 47
Wang, Y., Zhou, Y., Wang, Z., Ni, Y., Prud’homme, G. J., & WANG, Q. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf336 · Cited by 52
Oral Glucose Mobilizes Triglyceride Stores From the Human Intestine
Xiao, C., Stahel, P., Carreiro, A. L., Hung, Y.-H., Dash, S., Bookman, I. D., Buhman, K. K., & Lewis, G. F. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.10.002 · Cited by 46
Self-citationHiggins, V., Asgari, S., Hamilton, J. K., Wolska, A. T., Remaley, A. T., Hartmann, B., Holst, J. J., & Adeli, K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz261 · Cited by 44
Jácome-Sosa, M., Parks, E. J., Bruno, R. S., Tasali, E., Lewis, G. F., Schneeman, B. O., & Rains, T. M. (2016) · Advances in Nutrition · doi:10.3945/an.115.010397 · Cited by 49
Self-citationEnteroendocrine Regulation of Nutrient Absorption
McCauley, H. A. (2019) · Journal of Nutrition · doi:10.1093/jn/nxz191 · Cited by 48
Vergès, B. L., & Charbonnel, B. H. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30067-8 · Cited by 43
Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes
Taskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Pietiläinen, K. H., Ainola, M., Hakkarainen, A., Lundbom, N., Fuchs, J., Thorsell, A., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14328 · Cited by 40
Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism
Lutz, T. A., & Osto, E. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000293 · Cited by 39
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 42
Role of the Gut in Diabetic Dyslipidemia
Stahel, P., Xiao, C., Nahmias, A., & Lewis, G. F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00116 · Cited by 39
Self-citationMuzurović, E., & Mikhailidis, D. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1795132 · Cited by 35
Diabetic Dyslipidemia: From Evolving Pathophysiological Insight to Emerging Therapeutic Targets
Ng, D. S. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.062 · Cited by 35
Bozzetto, L., Annuzzi, G., Ragucci, M., Donato, O. D., Pepa, G. D., Corte, G. D., Griffo, E., Anniballi, G., Giacco, A., Mancini, M., et al. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.01.011 · Cited by 34
Bile acid treatment and FXR agonism lower postprandial lipemia in mice
Farr, S., Stankovic, B., HOFFMAN, S. S., Masoudpoor, H., Baker, C., Taher, J., Dean, A. E., Anakk, S., & Adeli, K. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00386.2018 · Cited by 35
Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance
Whyte, M. B., Shojaee-Moradie, F., Sharaf, S. E., Jackson, N. C., Fielding, B., Hovorka, R., Mendis, J., Russell-Jones, D., & Umpleby, A. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01176 · Cited by 32
Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB
Engelbrechtsen, L., Lundgren, J. R., Albrechtsen, N. J. W., Mahendran, Y., Iepsen, E. W., Finocchietto, P. V., Jonsson, A. E., Madsbad, S., Holst, J. J., Vestergaard, H., et al. (2017) · Obesity Science & Practice · doi:10.1002/osp4.133 · Cited by 33
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Tremblay, A. J., Lamarche, B., Kelly, I., Charest, A., Lépine, M. ‐., Droit, A., & Couture, P. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12359 · Cited by 32
Mulvihill, E. E. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000495 · Cited by 29
Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy
Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0483-3 · Cited by 30
Lipid effects of glucagon-like peptide 1 receptor analogs
Berberich, A. J., & Hegele, R. A. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000750 · Cited by 32
Functional food addressing heart health: do we have to target the gut microbiota?
Ryan, P. M., Ross, R. P., Fitzgerald, G. F., Caplice, N. M., & Stanton, C. (2015) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0000000000000224 · Cited by 28
Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association
Cariou, B. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30006-4 · Cited by 30
Wan, J., Ferrari, C., & Tadros, M. S. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15010014 · Cited by 32
Mori, K., Ishida, T., Yasuda, T., Monguchi, T., Sasaki, M., Kondo, K., Hasokawa, M., Nakajima, H., Haraguchi, Y., Sun, L., et al. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.02.005 · Cited by 27
Taher, J., Baker, C., ALVARES, D. C. L., Ijaz, L., Hussain, M. M., & Adeli, K. (2018) · Endocrinology · doi:10.1210/en.2018-00416 · Cited by 27
Lewis, G. F., & Hegele, R. A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00284-9 · Cited by 25
Self-citationA micro-nano optogenetic system based on probiotics for in situ host metabolism regulation
Zhang, X., Ma, N., Ling, W., Pang, G., Sun, T., Liu, J., Pan, H., Cui, M., Han, C., Yang, C., et al. (2022) · Nano Research · doi:10.1007/s12274-022-4963-5 · Cited by 24
Nahmias, A., Stahel, P., Tian, L., Xiao, C., & Lewis, G. F. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316311 · Cited by 23
Self-citationRecombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents
Ryan, P. M., Patterson, E., Kent, R. M., Stack, H. M., O’Connor, P. M., Murphy, K., Peterson, V. L., Mandal, R., Wishart, D. S., Dinan, T. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14010-x · Cited by 23
Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men
Matikainen, N., Björnson, E., Söderlund, S., Borén, C., Eliasson, B., Pietiläinen, K. H., Bogl, L. H., Hakkarainen, A., Lundbom, N. M. I., Rivellese, A. A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0145890 · Cited by 22
Multi-organ Coordination of Lipoprotein Secretion by Hormones, Nutrients and Neural Networks
Stahel, P., Xiao, C., Nahmias, A., Tian, L., & Lewis, G. F. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab008 · Cited by 24
Self-citationGlucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism
HOFFMAN, S. S., & Adeli, K. (2024) · Medical Review · doi:10.1515/mr-2024-0011 · Cited by 23
Central nervous system regulation of intestinal lipid and lipoprotein metabolism
Farr, S., Taher, J., & Adeli, K. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000254 · Cited by 21
Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors
Bistola, V., Lambadiari, V., Dimitriadis, G., Ioannidis, I., Makrilakis, K., Tentolouris, N., Τσάπας, Α., & Parissis, J. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9674-3 · Cited by 21
Beaudry, J. L., & Drucker, D. J. (2019) · Endocrinology · doi:10.1210/endocr/bqz029 · Cited by 22
Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies
Zhong, J., Kankanala, S., & Rajagopalan, S. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000340 · Cited by 19
The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia
Novodvorský, P., & Haluzı́k, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00982-3 · Cited by 19
Effect of liraglutide on dietary lipid‐induced insulin resistance in humans
Koška, J., Lopez, L. K., D’Souza, K. M., Osredkar, T., Deer, J., Kurtz, J., Salbe, A. D., Harman, S. M., & Reaven, P. D. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13037 · Cited by 21
Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus
Chiba, Y., Yamakawa, T., Tsuchiya, H., Oba, M. S., Suzuki, D., Danno, H., Takatsuka, Y., Shigematsu, H., Kaneshiro, M., & Terauchi, Y. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3464w · Cited by 18
Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
Teshome, G., Ambachew, S., Fasil, A., & Abebe, M. (2020) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s265631 · Cited by 19
Pepa, G. D., Patrício, B. G., Carli, F., Sabatini, S., Astiarraga, B., Ferrannini, E., Camastra, S., & Gastaldelli, A. (2024) · Diabetes · doi:10.2337/db23-0972 · Cited by 17
Morrow, N. M., Hanson, A. A., & Mulvihill, E. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.703966 · Cited by 17
GLP1, an Important Regulator of Intestinal Lipid Metabolism
Dallinga‐Thie, G. M., & Nieuwdorp, M. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305479 · Cited by 16
Alogliptin benzoate for the treatment of type 2 diabetes
Seino, Y., & Yabe, D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.898750 · Cited by 15
Diagnosis and management of lipodystrophy: a practical update
Stears, A. J., & Hames, C. (2014) · Clinical Lipidology · doi:10.2217/clp.14.13 · Cited by 15
Metadata
- Authors
- Xiao, C., Bandsma, R. H. J., Dash, S., Szeto, L., & Lewis, G. F.
- Affiliations
- University Medical Center Groningen (NL)
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2012-06
- Volume
- 32
- Issue
- 6
- Pages
- 1513-1519
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2100377339
- Cited by
- 164
- References
- 44
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 9 · 2023: 4 · 2022: 16 · 2021: 15 · 2020: 12 · 2019: 9 · 2018: 15 · 2017: 8 · 2016: 12 · 2015: 20 · 2014: 14 · 2013: 9 · 2012: 5
- FWCI
- 12.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- exenatide, GLP-1 receptor agonists, triglyceride-rich lipoproteins, apolipoprotein B-48, apolipoprotein B-100, lipoprotein clearance, postprandial lipemia, type 2 diabetes, incretin-based therapy, hepatic lipoprotein production
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Adult, Apolipoproteins B, Blood Glucose, C-Peptide, Glucagon, Humans, Hypoglycemic Agents, Insulin, Intestinal Mucosa, Intestines, Kinetics, Liver, Male, Models, Biological, Ontario, Peptides, Reference Values, Triglycerides, Venoms, Down-Regulation, Receptors, Glucagon, Postprandial Period, Apolipoprotein B-48, Apolipoprotein B-100
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
